STERIS plc (NYSE:STE) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in STERIS plc (NYSE:STE - Free Report) by 1.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 551,453 shares of the medical equipment provider's stock after purchasing an additional 6,334 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.56% of STERIS worth $133,749,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of STE. Bleakley Financial Group LLC raised its position in STERIS by 8.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider's stock worth $407,000 after buying an additional 134 shares during the last quarter. Assetmark Inc. lifted its position in STERIS by 24.6% during the third quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider's stock valued at $3,252,000 after purchasing an additional 2,647 shares during the period. BDF Gestion purchased a new stake in STERIS in the second quarter valued at $2,644,000. KBC Group NV grew its position in STERIS by 52.0% during the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider's stock worth $2,928,000 after purchasing an additional 4,132 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of STERIS by 7.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider's stock worth $390,880,000 after buying an additional 120,616 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

STERIS Trading Up 0.8 %

Shares of STE stock traded up $1.78 on Monday, hitting $216.12. 859,111 shares of the stock traded hands, compared to its average volume of 495,996. STERIS plc has a twelve month low of $195.47 and a twelve month high of $248.24. The stock has a market capitalization of $21.33 billion, a PE ratio of 48.94 and a beta of 0.85. The firm's 50-day moving average price is $227.28 and its two-hundred day moving average price is $228.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business had revenue of $1.33 billion during the quarter, compared to analysts' expectations of $1.33 billion. During the same quarter in the prior year, the company posted $2.03 EPS. The business's revenue for the quarter was up 7.3% on a year-over-year basis. As a group, analysts anticipate that STERIS plc will post 9.15 EPS for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio is presently 52.05%.

Insider Transactions at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company's stock, valued at $10,603,710. The trade was a 35.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on STE shares. JMP Securities reissued a "market outperform" rating and set a $265.00 price target on shares of STERIS in a report on Monday, November 18th. StockNews.com cut STERIS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, October 29th. Piper Sandler upgraded STERIS from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. KeyCorp upped their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 3rd. Finally, Stephens reiterated an "overweight" rating and issued a $260.00 target price on shares of STERIS in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.